Hypervision Surgical

Executive Summary

Hypervision Surgical is a UK-based medtech company pioneering AI-powered hyperspectral imaging for real-time intraoperative tissue characterization, initially targeting brain tumor resection. Founded in 2018 as a King’s College London spin-out, the company addresses the critical challenge of distinguishing tumor from healthy tissue during surgery without exogenous contrast agents. Its platform provides wide-field, label-free optical information that can be integrated into existing surgical workflows, aiming to improve precision, safety, and speed of complex procedures. By leveraging machine learning algorithms, the system interprets hyperspectral data to deliver actionable insights to surgeons, potentially reducing incomplete resections and improving patient outcomes. The technology is currently in the preclinical development stage, with plans to initiate first-in-human studies. Hypervision Surgical operates in a competitive landscape including intraoperative imaging and fluorescence-guided surgery, but its label-free, real-time approach offers differentiation. The company has raised undisclosed funding and is likely seeking additional capital to advance clinical validation. Given the significant unmet need in neurosurgery and the potential to expand into other surgical specialties, Hypervision Surgical presents a compelling investment thesis if clinical data validates its performance. The conviction score reflects early-stage technology risk balanced against strong technical foundation and clear clinical utility.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Clinical Study70% success
• Q2 2027Series A Funding Round80% success
• Q3 2026Partnership with a Major Neurosurgery Center60% success